BioSpace News Archive

Broken String Biosciences, a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, announced that its INDUCE-seq™ DNA break-mapping technology had been used in a peer-reviewed research paper to characterize off-target effects of CRISPR-Cas9 gene editing resulting from changes in DNA topology.

Palatin Technologies, Inc. (NYSE American: PTN) today announced plans to initiate a clinical study of melanocortin 4 receptor (MC4R) agonist, bremelanotide, an FDA approved product and 100% owned by Palatin, in combination with a Glucagon Like Peptide-1 (GLP-1) agonist, in obese patients in the first quarter of calendar year 2024.

TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis company, today announced that its executive management team will participate in the Jefferies Cannabis Summit being held on October 25, 2023 in New York City.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present 14 abstracts from across its sleep medicine portfolio, including two oral presentations, at the 17th annual World Sleep 2023 Congress, held October 20-25 in Rio de Janeiro, Brazil.

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2023.

X4 Pharmaceuticals, a company driven to improve the lives of people with rare diseases of the immune system, announced the appointment of R. Keith Woods as an independent director to the company’s Board of Directors.

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced that a late-breaking presentation highlighting results from the RESPONSE Phase 3 study of seladelpar in patients with primary biliary cholangitis (PBC) will be presented at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), in Boston, MA (November 10th – 14th).

The results of the PROTECT clinical trial shared today by Sanofi and presented at the International Society for Pediatric and Adolescent Diabetes (ISPAD) annual conference demonstrate that TZIELD, the first disease-modifying therapy available to delay clinical T1D in people at risk of developing the disease, can also be effective in newly diagnosed children and adolescents ages 8-17.

Regen BioPharma, Inc. (OTC-PINK: RGBP) (OTC-PINK: RGBPP) is currently developing a genetic approach to regulating NR2F6 levels in human T cells.

Akebia Therapeutics ® today announced that it will present data at the American Society of Nephrology Kidney Week 2023 (ASN Kidney Week), which will take place at the Pennsylvania Convention Center in Philadelphia from November 2-5, 2023.